ZLDAF (Zelira Therapeutics) Accounts Payable: $2.25 Mil (As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ZLDAF Zelira Therapeutics Ltd ZLDAF
9 GF Score
Price $0.30
GF Value $0.06
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Zelira Therapeutics Accounts Payable?

Zelira Therapeutics ZLDAF 9 Accounts Payable is $2.25 Mil as of Jun. 2025. GuruFocus rates ZLDAF with a GF Score™ of 9/100 and a GF Value™ of $0.06 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Zelira Therapeutics's Accounts Payable for the quarter that ended in Jun. 2025 was $2.25 Mil.

Zelira Therapeutics's quarterly Accounts Payable increased from Jun. 2024 ($2.26 Mil) to Dec. 2024 ($2.57 Mil) but then declined from Dec. 2024 ($2.57 Mil) to Jun. 2025 ($2.25 Mil).

Zelira Therapeutics's annual Accounts Payable increased from Jun. 2023 ($1.17 Mil) to Jun. 2024 ($2.26 Mil) but then declined from Jun. 2024 ($2.26 Mil) to Jun. 2025 ($2.25 Mil).

Zelira Therapeutics Accounts Payable Related Terms

Zelira Therapeutics Accounts Payable Historical Data

* Premium members only.

The historical data trend for Zelira Therapeutics's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zelira Therapeutics Accounts Payable Chart

Zelira Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.75 1.06 1.17 2.26 2.25

Zelira Therapeutics Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.17 2.34 2.26 2.57 2.25
ZLDAF
9GF Score
Zelira Therapeutics Ltd ZLDAF
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zelira Therapeutics Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of $2.25 Mil mean?
Zelira Therapeutics (ZLDAF) has a Accounts Payable of $2.25 Mil as of Jun. 2025. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Zelira Therapeutics and its competitors.
Is Zelira Therapeutics' Accounts Payable too high?
Zelira Therapeutics' current Accounts Payable is $2.25 Mil. Overall, Zelira Therapeutics has a GF Score™ of 9/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Zelira Therapeutics' Accounts Payable compare to MTNB and SXTP?
Zelira Therapeutics' Accounts Payable of $2.25 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Zelira Therapeutics and its competitors. Zelira Therapeutics's current Accounts Payable is $2.25 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zelira Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Zelira Therapeutics (ZLDAF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.06, compared to a current price of $0.30 — trading 400% above its estimated fair value. The current Accounts Payable is $2.25 Mil. Zelira Therapeutics' overall GF Score™ is 9/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Zelira Therapeutics (ZLDAF), the current Accounts Payable is $2.25 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zelira Therapeutics (ZLDAF) Overvalued in 2026?

Based on GuruFocus' analysis, Zelira Therapeutics stock appears to be overvalued. The current stock price of $0.30 is trading 400% above its estimated GF Value™ of $0.06. GuruFocus considers Zelira Therapeutics to be Significantly Overvalued.

Key valuation signals for ZLDAF:

  • Accounts Payable: $2.25 Mil
  • GF Value™: $0.06 vs. price of $0.30 (400% above fair value)
  • GF Score™: 9/100 with 7 warning signs

No single metric tells the full story. See the ZLDAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zelira Therapeutics Business Description

Address 101 St George’s Terrace, Level 3, Perth, WA, AUS, 6000
Zelira Therapeutics Ltd is a biotechnology company focused on developing a range of cannabinoid-based formulations for the treatment of various medical conditions in Australia. The company is involved in a human clinical trial program focused on insomnia, autism, and eczema, and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer. The company is organised into two operating segments based on geographic location of operations: Australia and United States of America.
9GF Score

Get the complete analysis for ZLDAF

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.30
Price
$0.06
GF Value